Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care

Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma

Patient treatment preferences in relapsed/refractory multiple myeloma

Landscape change with oral proteasome maintenance in multiple myeloma patients

The importance of NF-kB pathway in myeloma

Multiple myeloma highlights and more from ASH 2018

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia

An integrated view of the role of the B cell antigen receptor in lymphoma cell fitness

Myeloma XI study: Quadruplet regimen for transplant eligible patients

Developments in CAR T treatments for adult patients

Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy